Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients

Patrizia Vici, Laura Pizzuti, Luigi Di Lauro, Laura Conti, Chiara Mandoj, Anna Antenucci, G. Digiesi, Domenico Sergi, A. Amodio, Paolo Marchetti, F. Sperati, Mario Valle, Alfredo Garofalo, Enrico Vizza, Giacomo Corrado, C. Vincenzoni, Federica Tomao, Ramy Kayal, Annalise Marsella, Mariantonia Carosi & 4 others B. Antoniani, Antonio Giordano, Marcello Maugeri-Saccà, Maddalena Barba

Research output: Contribution to journalArticle

Abstract

Background: Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. Results: For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.

Original languageEnglish
Pages (from-to)516-522
Number of pages7
JournalJournal of Cancer
Volume7
Issue number5
DOIs
Publication statusPublished - 2016

Fingerprint

Glucose
Fasting
Body Mass Index
Neoplasms
Therapeutics
Aptitude
National Cancer Institute (U.S.)
Ovarian epithelial cancer
Platinum
Ovarian Neoplasms
Italy
Population
Carcinogenesis

Keywords

  • Body mass index
  • Epithelial ovarian cancer
  • Fasting glucose
  • FIGO stage
  • Tumour grade

ASJC Scopus subject areas

  • Oncology

Cite this

Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients. / Vici, Patrizia; Pizzuti, Laura; Di Lauro, Luigi; Conti, Laura; Mandoj, Chiara; Antenucci, Anna; Digiesi, G.; Sergi, Domenico; Amodio, A.; Marchetti, Paolo; Sperati, F.; Valle, Mario; Garofalo, Alfredo; Vizza, Enrico; Corrado, Giacomo; Vincenzoni, C.; Tomao, Federica; Kayal, Ramy; Marsella, Annalise; Carosi, Mariantonia; Antoniani, B.; Giordano, Antonio; Maugeri-Saccà, Marcello; Barba, Maddalena.

In: Journal of Cancer, Vol. 7, No. 5, 2016, p. 516-522.

Research output: Contribution to journalArticle

Vici, P, Pizzuti, L, Di Lauro, L, Conti, L, Mandoj, C, Antenucci, A, Digiesi, G, Sergi, D, Amodio, A, Marchetti, P, Sperati, F, Valle, M, Garofalo, A, Vizza, E, Corrado, G, Vincenzoni, C, Tomao, F, Kayal, R, Marsella, A, Carosi, M, Antoniani, B, Giordano, A, Maugeri-Saccà, M & Barba, M 2016, 'Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients', Journal of Cancer, vol. 7, no. 5, pp. 516-522. https://doi.org/10.7150/jca.13578
Vici, Patrizia ; Pizzuti, Laura ; Di Lauro, Luigi ; Conti, Laura ; Mandoj, Chiara ; Antenucci, Anna ; Digiesi, G. ; Sergi, Domenico ; Amodio, A. ; Marchetti, Paolo ; Sperati, F. ; Valle, Mario ; Garofalo, Alfredo ; Vizza, Enrico ; Corrado, Giacomo ; Vincenzoni, C. ; Tomao, Federica ; Kayal, Ramy ; Marsella, Annalise ; Carosi, Mariantonia ; Antoniani, B. ; Giordano, Antonio ; Maugeri-Saccà, Marcello ; Barba, Maddalena. / Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients. In: Journal of Cancer. 2016 ; Vol. 7, No. 5. pp. 516-522.
@article{0e0f42c469d94c1b9262bf203c37dd0f,
title = "Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients",
abstract = "Background: Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. Results: For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7{\%}, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95{\%} CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.",
keywords = "Body mass index, Epithelial ovarian cancer, Fasting glucose, FIGO stage, Tumour grade",
author = "Patrizia Vici and Laura Pizzuti and {Di Lauro}, Luigi and Laura Conti and Chiara Mandoj and Anna Antenucci and G. Digiesi and Domenico Sergi and A. Amodio and Paolo Marchetti and F. Sperati and Mario Valle and Alfredo Garofalo and Enrico Vizza and Giacomo Corrado and C. Vincenzoni and Federica Tomao and Ramy Kayal and Annalise Marsella and Mariantonia Carosi and B. Antoniani and Antonio Giordano and Marcello Maugeri-Sacc{\`a} and Maddalena Barba",
year = "2016",
doi = "10.7150/jca.13578",
language = "English",
volume = "7",
pages = "516--522",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "5",

}

TY - JOUR

T1 - Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients

AU - Vici, Patrizia

AU - Pizzuti, Laura

AU - Di Lauro, Luigi

AU - Conti, Laura

AU - Mandoj, Chiara

AU - Antenucci, Anna

AU - Digiesi, G.

AU - Sergi, Domenico

AU - Amodio, A.

AU - Marchetti, Paolo

AU - Sperati, F.

AU - Valle, Mario

AU - Garofalo, Alfredo

AU - Vizza, Enrico

AU - Corrado, Giacomo

AU - Vincenzoni, C.

AU - Tomao, Federica

AU - Kayal, Ramy

AU - Marsella, Annalise

AU - Carosi, Mariantonia

AU - Antoniani, B.

AU - Giordano, Antonio

AU - Maugeri-Saccà, Marcello

AU - Barba, Maddalena

PY - 2016

Y1 - 2016

N2 - Background: Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. Results: For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.

AB - Background: Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. Results: For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.

KW - Body mass index

KW - Epithelial ovarian cancer

KW - Fasting glucose

KW - FIGO stage

KW - Tumour grade

UR - http://www.scopus.com/inward/record.url?scp=84971571560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971571560&partnerID=8YFLogxK

U2 - 10.7150/jca.13578

DO - 10.7150/jca.13578

M3 - Article

VL - 7

SP - 516

EP - 522

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 5

ER -